Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis

July 27, 2015 updated by: Almirall, S.A.

Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II

The purpose of this study is to investigate the efficacy of LAS41005 in comparison to placebo and to LAS106521 in actinic keratosis (AK).

Study Overview

Status

Completed

Conditions

Detailed Description

To investigate as primary objective:

  • Superiority to placebo and non-inferiority to LAS106521 measured by histological clearance of one predefined target lesion;

To investigate as secondary objective:

  • Superiority to LAS106521
  • Improvement of treated lesions (lesion response)
  • Assessment of tolerability and safety by physicians global assessment score (PGA, PGT)
  • Patient's assessment of tolerability and efficacy and patient's compliance

Study Type

Interventional

Enrollment (Actual)

470

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Altenkirchen, Germany, 57610
        • Almirall Facility Site#37
      • Augsburg, Germany, 86163
        • Almirall Facility Site#24
      • Augsburg, Germany, 86179
        • Almirall Facility Site#23
      • Berlin, Germany, 10117
        • Almirall Facility Site#01
      • Berlin, Germany, 10437
        • Almirall Facility Site#28
      • Berlin, Germany, 10827
        • Almirall Facility Site#02
      • Berlin, Germany, 10967
        • Almirall Facility Site#34
      • Berlin, Germany, 12353
        • Almirall Facility Site#35
      • Bonn, Germany, 53111
        • Almirall Facility Site#31
      • Buxtehude, Germany, 21614
        • Almirall Facility Site#04
      • Detmold, Germany, 32756
        • Almirall Facility Site#40
      • Dresden, Germany, 01097
        • Almirall Facility Site#30
      • Dülmen, Germany, 48249
        • Almirall Facility Site#11
      • Düsseldorf, Germany, 40225
        • Almirall Facility Site#12
      • Frankfurt, Germany, 60590
        • Almirall Facility Site#17
      • Freiburg, Germany, 79104
        • Almirall Facility Site#22
      • Friedrichshafen, Germany, 88045
        • Almirall Facility Site#36
      • Fulda, Germany, 36037
        • Almirall Facility Site#19
      • Göttingen, Germany, 37075
        • Almirall Facility Site#32
      • Hamburg, Germany, 20148
        • Almirall Facility Site#09
      • Jena, Germany, 07740
        • Almirall Facility Site#29
      • Kiel, Germany, 24103
        • Almirall Facility Site#07
      • Kiel, Germany, 24105
        • Almirall Facility Site#08
      • Koblenz, Germany, 56068
        • Almirall Facility Site#15
      • Landau, Germany, 76829
        • Almirall Facility Site#21
      • Leipzig, Germany, 04103
        • Almirall Facility Site#27
      • Lübeck, Germany, 23538
        • Almirall Facility Site#06
      • Mahlow, Germany, 15831
        • Almirall Facility Site#03
      • München, Germany, 80337
        • Almirall Facility Site#25
      • München, Germany, 81476
        • Almirall Facility Site#39
      • Nördlingen, Germany, 86720
        • Almirall Facility Site#33
      • Osnabrück, Germany, 49078
        • Almirall Facility Site#38
      • Pinneberg, Germany, 25421
        • Almirall Facility Site#05
      • Quedlinburg, Germany, 06484
        • Almirall Facility Site#26
      • Radolfzell, Germany, 78315
        • Almirall Facility Site#20
      • Salzwedel, Germany, 29410
        • Almirall Facility Site#10
      • Soest, Germany, 59494
        • Almirall Facility Site#16
      • Vechta, Germany, 49377
        • Almirall Facility Site#14
      • Wiesbaden, Germany, 65191
        • Almirall Facility Site#18
      • Wuppertal, Germany, 42275
        • Almirall Facility Site#13

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Main Inclusion Criteria:

  • Have at least 4 but not more than 10 clinically confirmed AK target lesions of mild to moderate intensity within the face/forehead or bald scalp (excluding eyelids, lips, and mucosa), i.e. actinic keratosis grade I and II according to Olsen EA et al. 1991
  • Woman of childbearing potential are allowed to participate in this study only if they use a highly effective method of contraception

Main Exclusion Criteria:

  • Have received effective treatment of AK in the three months preceding this clinical trial
  • Have known hypersensitivity to LAS41005 or LAS106521
  • Have currently other malignant or benign tumors of the skin within the treatment area (e.g. malignant melanoma, basal cell carcinoma, squamous cell carcinoma)
  • Patient's taking phenytoin
  • Show cornu cutaneum like alterations of the skin in the face or the bald scalp (target area)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: QUADRUPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
PLACEBO_COMPARATOR: Placebo
Topical
EXPERIMENTAL: LAS41005
Topical
ACTIVE_COMPARATOR: LAS106521
Topical

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Histological status of AK target lesion
Time Frame: Day 140
Day 140

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Estrella Garcia, MD, MBA, Almirall Hermal GmbH

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

June 1, 2008

Primary Completion (ACTUAL)

June 1, 2009

Study Completion (ACTUAL)

June 1, 2009

Study Registration Dates

First Submitted

September 29, 2009

First Submitted That Met QC Criteria

September 29, 2009

First Posted (ESTIMATE)

September 30, 2009

Study Record Updates

Last Update Posted (ESTIMATE)

July 28, 2015

Last Update Submitted That Met QC Criteria

July 27, 2015

Last Verified

July 1, 2015

More Information

Terms related to this study

Other Study ID Numbers

  • H 1005 6002 - 0702
  • EudraCT: 2007-003889-18

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe